RedHill Biopharma (RDHL) Profit After Tax (2016 - 2023)
Historic Profit After Tax for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $101.2 million.
- RedHill Biopharma's Profit After Tax rose 76451.2% to $101.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 5983.41%. This contributed to the annual value of -$8.3 million for FY2024, which is 13457.1% down from last year.
- Latest data reveals that RedHill Biopharma reported Profit After Tax of $101.2 million as of Q2 2023, which was up 76451.2% from -$50.2 million recorded in Q1 2023.
- In the past 5 years, RedHill Biopharma's Profit After Tax registered a high of $101.2 million during Q2 2023, and its lowest value of -$145.2 million during Q4 2021.
- For the 5-year period, RedHill Biopharma's Profit After Tax averaged around -$591333.3, with its median value being $11.8 million (2019).
- Its Profit After Tax has fluctuated over the past 5 years, first crashed by 106284.39% in 2021, then surged by 76451.2% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Profit After Tax stood at $11.8 million in 2019, then increased by 27.44% to $15.1 million in 2020, then crashed by 1062.84% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then soared by 245.63% to $101.2 million in 2023.
- Its Profit After Tax was $101.2 million in Q2 2023, compared to -$50.2 million in Q1 2023 and -$69.5 million in Q4 2022.